BioCentury
ARTICLE | Financial News

ICER finds Lemtrada most cost-effective in MS

January 27, 2017 11:13 PM UTC

In an evidence report evaluating disease-modifying therapies for multiple sclerosis, the Institute for Clinical and Economic Review said Lemtrada alemtuzumab from Sanofi (Euronext:SAN; NYSE:SNY) "consistently demonstrated improved health outcomes and good value" at a lower cost than other treatments.

ICER compared the effectiveness and value of 15 therapies, including several interferons; Copaxone glatiramer acetate and its generic competitor Glatopa; Tecfidera dimethyl fumarate; Gilenya fingolimod; and Zinbryta daclizumab in a network meta-analysis that included 35 randomized trials with over 21,789 patients...